Determining the Impact of Cannabis Use and Severity on Tobacco Cessation Outcomes: Study Protocol for a Prospective Tobacco Treatment Trial

Overview

Journal BMC Psychol

Publisher Biomed Central

Specialty Psychology

Date 2023 Jan 26

PMID 36698194

Authors

Kyle J Walters

Nathaniel L Baker

Rachel L Tomko

Kevin M Gray

Matthew J Carpenter

Erin A McClure

Affiliations

Soon will be listed here.

Abstract

Background: Several evidence-based tobacco cessation treatment strategies exist, though significant barriers to cessation remain which must be addressed to improve abstinence rates for sub-populations of those smoking cigarettes. Cannabis co-use among those who use tobacco is common and appears to be increasing among adults in the United States (US). The literature evaluating the impact of cannabis use on tobacco cessation has been mixed and has several important limitations, which precludes development of treatment recommendations specific to individuals who use tobacco and co-use cannabis. To date, no prospective studies have evaluated the impact of cannabis use and severity on tobacco cessation or quantified cannabis use changes during tobacco treatment to assess for concurrent reductions, abstinence, or compensatory (i.e., increased) cannabis use. This study's aims are to: (1) evaluate tobacco cessation outcomes among participants who co-use cannabis compared to participants only using tobacco, (2) using daily diaries and biochemical verification, assess changes in cannabis use during tobacco treatment, and (3) assess for a dose-dependent impact of cannabis use on tobacco cessation.

Method: A multi-site, prospective, quasi-experimental 12-week tobacco treatment trial enrolling treatment-seeking adults (ages 18-40; N = 208) from three sites across South Carolina (US) who use tobacco daily and oversampling (2:1) those who co-use cannabis. Participants receive tobacco cessation pharmacotherapy (varenicline) paired with behavioral support, while cannabis use is not addressed as part of treatment. The primary outcome is 7-day point prevalence tobacco abstinence at the week 12 end of treatment visit, measured via biochemical verification and self-report. Secondary outcome measures include changes in cannabis use (via biochemical verification and self-report) during tobacco cessation treatment.

Discussion: Results from this trial have the potential to inform tobacco treatment among those co-using cannabis, which may require a tailored approach to address the role of cannabis in quitting tobacco.

Trial Registration: The trial is registered with ClinicalTrials.gov: NCT04228965. January 14th, 2020.

References

Hindocha C, McClure E . Unknown population-level harms of cannabis and tobacco co-use: if you don't measure it, you can't manage it. Addiction. 2020; 116(7):1622-1630. PMC: 8041912. DOI: 10.1111/add.15290. View

Cohn A, Chen S . Age groups differences in the prevalence and popularity of individual tobacco product use in young adult and adult marijuana and tobacco co-users and tobacco-only users: Findings from Wave 4 of the population assessment of tobacco and health study. Drug Alcohol Depend. 2022; 233():109278. PMC: 9028208. DOI: 10.1016/j.drugalcdep.2022.109278. View

Walsh H, McNeill A, Purssell E, Duaso M . A systematic review and Bayesian meta-analysis of interventions which target or assess co-use of tobacco and cannabis in single- or multi-substance interventions. Addiction. 2020; 115(10):1800-1814. DOI: 10.1111/add.14993. View

Mariani J, Brooks D, Haney M, Levin F . Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. Drug Alcohol Depend. 2010; 113(2-3):249-51. PMC: 3025094. DOI: 10.1016/j.drugalcdep.2010.08.008. View

Pacek L, Vandrey R, Dermody S, Denlinger-Apte R, Lemieux A, Tidey J . Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use. Drug Alcohol Depend. 2016; 167:228-32. PMC: 5037041. DOI: 10.1016/j.drugalcdep.2016.08.620. View

Sobell L, Sobell M, Leo G, Cancilla A . Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict. 1988; 83(4):393-402. DOI: 10.1111/j.1360-0443.1988.tb00485.x. View

Tomko R, Gray K, Oppenheimer S, Wahlquist A, McClure E . Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. Am J Drug Alcohol Abuse. 2018; 45(1):26-41. PMC: 6128791. DOI: 10.1080/00952990.2018.1437445. View

Schauer G, Peters E . Correlates and trends in youth co-use of marijuana and tobacco in the United States, 2005-2014. Drug Alcohol Depend. 2018; 185:238-244. DOI: 10.1016/j.drugalcdep.2017.12.007. View

McRae-Clark A, Gray K, Baker N, Sherman B, Squeglia L, Sahlem G . Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021; 229(Pt B):109111. PMC: 8665036. DOI: 10.1016/j.drugalcdep.2021.109111. View

10.

Westmaas J, Strollo S, Newton C, Carter B, Diver W, Flanders W . Association between Smoking Cannabis and Quitting Cigarettes in a Large American Cancer Society Cohort. Cancer Epidemiol Biomarkers Prev. 2021; 30(10):1956-1964. PMC: 9398124. DOI: 10.1158/1055-9965.EPI-20-1810. View

11.

Weinberger A, Wyka K, Kim J, Smart R, Mangold M, Schanzer E . A difference-in-difference approach to examining the impact of cannabis legalization on disparities in the use of cigarettes and cannabis in the United States, 2004-17. Addiction. 2022; 117(6):1768-1777. DOI: 10.1111/add.15795. View

12.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

13.

Tomko R, Baker N, McClure E, Sonne S, McRae-Clark A, Sherman B . Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2017; 182:1-7. PMC: 5742553. DOI: 10.1016/j.drugalcdep.2017.09.035. View

14.

Tsai J, Rolle I, Singh T, Boulet S, McAfee T, Grant A . Patterns of marijuana and tobacco use associated with suboptimal self-rated health among US adult ever users of marijuana. Prev Med Rep. 2017; 6:251-257. PMC: 5382028. DOI: 10.1016/j.pmedr.2017.03.014. View

15.

Smith D, OConnor R, Wei B, Travers M, Hyland A, Goniewicz M . Nicotine and Toxicant Exposure Among Concurrent Users (Co-Users) of Tobacco and Cannabis. Nicotine Tob Res. 2019; 22(8):1354-1363. PMC: 7364847. DOI: 10.1093/ntr/ntz122. View

16.

McClure E, Baker N, Hood C, Tomko R, Squeglia L, Flanagan J . Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults. Nicotine Tob Res. 2019; 22(8):1374-1382. PMC: 7364825. DOI: 10.1093/ntr/ntz170. View

17.

McClure E, Rabin R, Lee D, Hindocha C . Treatment Implications Associated with Cannabis and Tobacco Co-Use. Curr Addict Rep. 2021; 7(4):533-544. PMC: 7992053. DOI: 10.1007/s40429-020-00334-8. View

18.

Robinson S, Sobell L, Sobell M, Leo G . Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav. 2013; 28(1):154-62. DOI: 10.1037/a0030992. View

19.

DAgostino Jr R . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19):2265-81. DOI: 10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b. View

20.

Gravely S, Driezen P, Smith D, Borland R, Lindblom E, Hammond D . International differences in patterns of cannabis use among adult cigarette smokers: Findings from the 2018 ITC Four Country Smoking and Vaping Survey. Int J Drug Policy. 2020; 79:102754. PMC: 7967289. DOI: 10.1016/j.drugpo.2020.102754. View